EGFR mutations in malignant pleural effusion of non-small cell lung cancer: a case report.

[1]  C. Tzen,et al.  Female sex and bronchioloalveolar pathologic subtype predict EGFR mutations in non-small cell lung cancer. , 2005, Chest.

[2]  W. Park,et al.  Absence of EGFR mutation in the kinase domain in common human cancers besides non‐small cell lung cancer , 2005, International journal of cancer.

[3]  Takayuki Kosaka,et al.  Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer , 2004, Cancer Research.

[4]  R. Herbst,et al.  Overview of the current status of human epidermal growth factor receptor inhibitors in lung cancer. , 2004, Clinical lung cancer.

[5]  R. Wilson,et al.  EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[6]  A. Bezjak,et al.  A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial , 2004 .

[7]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[8]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[9]  Jin H. Lee,et al.  p53 and FHIT mutations and microsatellite alterations in malignancy-associated pleural effusion. , 2004, Lung cancer.

[10]  M. Nakamoto,et al.  K-ras and rho A mutations in malignant pleural effusion. , 2001, International journal of oncology.

[11]  A. Patchefsky,et al.  Case report 3 , 1976, Skeletal Radiology.